Last reviewed · How we verify
NCT03801109
Transcranial Magnetic Stimulation and Hyperbaric Chamber for Women Fibromyalgia
NA trial testing Hyperbaric group in Fibromyalgia in 69 participants. Completed in 26 June 2020.
23 December 2019
Quick facts
| Lead sponsor | University of Valencia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 69 |
| Start date | 1 February 2019 |
| Primary completion | 23 December 2019 |
| Estimated completion | 26 June 2020 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Hyperbaric group
- Magnetic group
- Physical group
- Baseline group
Conditions studied
- Fibromyalgia — all drugs for Fibromyalgia →
Sponsor
University of Valencia
Who can join
Adults 40 to 70, female only, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Fibromyalgia syndrome (FMS) is a multisystem disease, characterized by generalized chronic musculoskeletal pain. In addition, there is a lot of care for fatigue, sleep disorders, morning stiffness, cognitive disorders, depression, anxiety and stress. Other common symptoms are back pain, headaches, irritable bowel, balance problems and deterioration of physical function in general. Patients with fibromyalgia (FM) often show pain at specific points that are known as "tender spots or tender spots, with an increased sensitivity to painful stimuli" (hyperalgesia) and a decreased pain threshold (allodynia). which can be evidenced in the physical examination and in the absence of anomalies that justify in the biological or image tests. These pain points to pressure, based on the most specific and specific criteria for the diagnosis of the disease, traditionally based on the criteria of the American College of Rheumatology (ACR), according to which, should be presented so minus 11 out of 18 painful points to confirm it. Although the etiology remains unknown and unclear, its appearance is attributed to a problem of central sensitization, that is, changes in central processing, which causes an alteration of the mechanisms that regulate the sensation of pain, with amplification of nociceptive input . and perpetuation of painful stimuli. Fibromyalgia is becoming a common syndrome in the countries of Western Europe, with a prevalence in the general population that ranges between 1-3%, and specifically in Spain, around 2.4%. In addition, it has a higher incidence in women than men (73-95%), predominantly affecting women between the ages of 40-50 years. About 3% of women with fibromyalgia are at an age when menopause occurs, so not only do they experience the symptoms of both states but they even exacerbate the syndrome with each other. On the other hand, and in relation to its chronicity, the care of this type of patients involves large costs for society with a significant consumption of health resources in the field of primary care, as well as the costs of work absenteeism. For these reasons, it is considered an important problem with a great impact on the health system, and therefore more and more studies are being developed with the aim of better understanding the pathophysiology of this disease. The therapeutic approach includes low cost and easy access measures, such as physical exercise (EF) programs to improve the symptoms of FM. Physical exercise has positive effects directly on pain, joint and muscle stiffness, generalized sensitivity and fatigue, among others, and secondarily on cognitive disorders. Thus, the vast majority of studies focus on low-impact aerobic exercise, performed between 60% and 70% of the maximum heart rate two to three times a week. However, to date, there is no study that compares the effectiveness of physical exercise with other innovative therapeutic actions, such as transcranial magnetic stimulation (TMS), the hyperbaric chamber (HBOT), in parameters related to pain and quality of life. the life of patients with fibromyalgia. The general objective is the effectiveness of transcranial magnetic stimulation and the hyperbaric chamber in women with fibromyalgia. As specific objectives we propose: To assess the effect of HBOT, TMS and EF on quality of life in women with fibromyalgia. * Object the effect of HBOT, TMS and EF in cortical functioning. * Evaluate the effect of HBOT, TMS and EF on fatigue. * Evaluate the effect of HBOT, TMS and EF on psychological aspects, such as depression and anxiety. * Evaluate the effect of HBOT, TMS and EF on the perception of pain and the number of painful points. * Evaluate the effect of HBOT, TMS and EF on the quality of sleep. * Evaluate the effect of HBOT, TMS and EF on the quality of life. * Evaluate the effect of HBOT, TMS and EF on the pain constructs. * Determine the effect of HBOT, TMS and EF on plasma endorphin levels.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Low-Intensity Physical Exercise Improves Pain Catastrophizing and Other Psychological and Physical Aspects in Women with Fibromyalgia: A Randomized Controlled Trial.
Izquierdo-Alventosa R, Inglés M, Cortés-Amador S, Gimeno-Mallench L, et al · · 2020 · cited 73× · PMID 32455853 · DOI 10.3390/ijerph17103634 -
Comparative study of the effectiveness of a low-pressure hyperbaric oxygen treatment and physical exercise in women with fibromyalgia: randomized clinical trial.
Izquierdo-Alventosa R, Inglés M, Cortés-Amador S, Gimeno-Mallench L, et al · · 2020 · cited 16× · PMID 32636943 · DOI 10.1177/1759720x20930493 -
Effects of a low-pressure hyperbaric oxygen therapy on psychological constructs related to pain and quality of life in women with fibromyalgia: A randomized clinical trial.
Izquierdo-Alventosa R, Inglés M, Cortés-Amador S, Muñoz-Gómez E, et al · · 2024 · cited 1× · PMID 38383268 · DOI 10.1016/j.medcli.2023.12.016
Verify or expand the search:
- PubMed search for NCT03801109
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fibromyalgia
Currently open trials in the same condition.
- NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
- NCT07245303 — Neural Mechanisms of Light Driven Analgesia · NA · recruiting
- NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
- NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
- NCT07465991 — The Effect of Digital Cognitive Behavioural Therapy for Insomnia on Physical Activity in Fibromyalgia · NA · recruiting
Other University of Valencia trials
Trials by the same sponsor.
- NCT07509281 — Peri-implant Tissues Changes for Different Abutment Shapes and Heights · NA · not yet recruiting
- NCT07535528 — Implant Placement Depth and Peri-Implant Tissue Outcomes · NA · not yet recruiting
- NCT07471555 — Vascular Access and Intraosseus · NA · enrolling by invitation
- NCT07463066 — Long-Term Effectiveness of Pain Neuroscience Education in Women With Genito-Pelvic Pain/Penetration Disorder. · not yet recruiting
- NCT07419399 — Acute Effects of Radiofrequency Diathermy in Postpartum Women With Diastasis Abdominis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03801109 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Valencia
- Last refreshed: 26 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03801109.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing